Suppr超能文献

比马前列素治疗眉毛稀少症的治疗潜力。

Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis.

作者信息

Chanasumon Nongsak, Sriphojanart Tueboon, Suchonwanit Poonkiat

机构信息

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

出版信息

Drug Des Devel Ther. 2018 Feb 22;12:365-372. doi: 10.2147/DDDT.S156467. eCollection 2018.

Abstract

Eyebrows serve as a key feature of the face and have many roles, including cosmetic appearance and social communication. Eyebrow hypotrichosis, which refers to reduction or absence of the eyebrow hair, could be a major problem that leads to negative functional, psychological, and social consequences. Bimatoprost is an ophthalmic prostamide analog that is approved by the United States Food and Drug Administration for the treatment of eyelash hypotrichosis. Its proposed mechanism is stimulation of the prostaglandin receptor in dermal papilla and melanocyte, thus leading to a prolonged anagen phase and increased melanogenesis. The hair follicle then increases in thickness, length, and darkness. The efficacy of bimatoprost for the treatment of eyebrow hypotrichosis has been supported by well-controlled studies. Bimatoprost, which is noninvasive, effective, and well tolerated, is worth considering as a treatment option for eyebrow hypotrichosis.

摘要

眉毛是面部的一个关键特征,具有多种作用,包括外观修饰和社交交流。眉毛毛发稀少症是指眉毛毛发减少或缺失,这可能是一个导致负面功能、心理和社会后果的主要问题。比马前列素是一种眼科前列腺素类似物,已被美国食品药品监督管理局批准用于治疗睫毛稀少症。其推测机制是刺激真皮乳头和黑素细胞中的前列腺素受体,从而导致生长期延长和黑素生成增加。然后毛囊在厚度、长度和颜色上都会增加。对照良好的研究支持了比马前列素治疗眉毛毛发稀少症的疗效。比马前列素具有非侵入性、有效性和良好的耐受性,值得作为眉毛毛发稀少症的一种治疗选择加以考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55b0/5826207/a53570df3b6d/dddt-12-365Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验